KOD - Kodiak Sciences: Generation 2.0 Therapies Against Common Retinal Diseases
Kodiak Sciences (KOD) is based in Palo Alto, California. The company is developing Generation 2.0 therapies against common retinal diseases using its antibody biopolymer conjugates technology. The technology allows increased durability, bioavailability, biocompatibility, and stability of the drug. Using the technology, higher amounts of drug can be administered per dose (with increased half-life), thus reducing the frequency of administration and resulting in increased convenience for patients in the form of reduced number of visits to a physician’s office to get intravitreal injections.
Age-related macular degeneration, AMD is a degenerative disease of the retina that results